Alek Safarian is the CEO of venture investment firm, ALSA Holdings Ltd.  Alek has a diverse background in drug development spanning some 30 years.  Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific.  He subsequently founded Novotech, a Sydney based contract research organisation working with hundreds of clinical stage biotech companies over a 21 year period.  Alek holds a B. Pharm and MBA from the University of Sydney.